TenNor Enters Research Collaboration with Janssen for Potential New Treatments for Nontuberculous Mycobacteria Diseases

TenNor Enters Research Collaboration with Janssen for Potential New Treatments for Nontuberculous Mycobacteria Diseases
News provided by
Share this article
Share this article
SUZHOU, China, Jan. 18, 2021 /PRNewswire/ -- TenNor Therapeutics (Suzhou) Limited, a clinical-stage biopharmaceutical company dedicated to research and development of differentiated products for the treatment of diseases associated with bacterial infections and dysbioses, announced today that it has entered into a research collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. As part of the agreement, the parties plan to utilize a multitargeting drug conjugation platform developed by TenNor to discover new therapies for the treatment of nontuberculous mycobacteria (NTM) diseases. The agreement was facilitated by Johnson & Johnson Innovation LLC.

Related Keywords

China ,Shanghai ,Suzhou ,Jiangsu , ,Tennor Therapeutics ,Johnson Innovation ,Janssen Pharmaceuticals Inc ,Tennor Therapeutics Suzhou ,Janssen Pharmaceutical Companies Of Johnson ,Janssen Pharmaceuticals ,Janssen Pharmaceutical Companies ,Nor Therapeutics ,Tennor Therapeutics Limited ,சீனா ,ஷாங்காய் ,சூழோ ,ஜான்சன் கண்டுபிடிப்பு ,ஜான்சன் மருந்துகள் இன்க் ,ஜான்சன் மருந்து நிறுவனங்கள் ஆஃப் ஜான்சன் ,ஜான்சன் மருந்துகள் ,ஜான்சன் மருந்து நிறுவனங்கள் ,அல்லது சிகிச்சை ,